文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

脐带血辅助单倍体外周血干细胞移植与无关供者外周血干细胞移植治疗恶性血液病的比较

[Haploidentical donor peripheral blood stem cell transplantation using third-party cord blood compared with matched unrelated donor transplantation for patients with hematologic malignancies].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

该回顾性分析纳入中南大学湘雅医院2016年1月至2021年12月接受脐带血辅助单倍体外周血干细胞移植(haplo-cord-PBSCT)的104例和接受无关供者外周血干细胞移植(UD-PBSCT)的52例恶性血液病患者,比较两组植入、移植物抗宿主病(GVHD)、复发、非复发死亡及生存情况。结果显示两组疗效和安全性相似,haplo-cord-PBSCT可作为恶性血液病的替代治疗方案。

要点

  • haplo-cord-PBSCT组与UD-PBSCT组中性粒细胞和血小板中位植入时间及累积植入率均无显著差异。
  • 两组100天内Ⅱ~Ⅳ度及Ⅲ/Ⅳ度急性GVHD、2年慢性GVHD及重度慢性GVHD累积发生率均无显著差异。
  • 两组2年累积复发率、非复发死亡率、总生存率、无病生存率及无GVHD无复发生存率均无显著差异。

核心结论

  • haplo-cord-PBSCT与UD-PBSCT治疗恶性血液病具有相似的疗效和安全性,可作为恶性血液病的替代治疗方案。

研究设计与样本

  • 回顾性分析中南大学湘雅医院2016年1月至2021年12月接受haplo-cord-PBSCT的104例和接受UD-PBSCT的52例恶性血液病患者。

主要发现

  • haplo-cord-PBSCT组与UD-PBSCT组中性粒细胞中位植入时间分别为13(9~22)d和13(10~24)d(P=0.834),血小板中位植入时间分别为15(7~103)d和14(8~38)d(P=0.816)。
  • haplo-cord-PBSCT组与UD-PBSCT组移植后30 d中性粒细胞累积植入率均为100.0%(P=0.314),移植后100 d血小板累积植入率分别为95.2%(95%CI 88.3%~98.1%)和100.0%(P=0.927)。
  • 移植后30 d两组患者均达到完全供者嵌合状态,未发生脐带血干细胞植入。
  • haplo-cord-PBSCT组与UD-PBSCT组移植后100 d内Ⅱ~Ⅳ度急性GVHD累积发生率分别为29.1%(95%CI 20.1%~38.1%)和28.8%(95%CI 17.2%~41.6%)(P=0.965),Ⅲ/Ⅳ度急性GVHD累积发生率分别为7.8%(95%CI 3.6%~14.0%)和9.6%(95%CI 3.5%~19.5%)(P=0.725)。
  • haplo-cord-PBSCT组与UD-PBSCT组2年慢性GVHD累积发生率分别为45.3%(95%CI 36.1%~56.1%)和35.1%(95%CI 21.6%~44.1%)(P=0.237),移植后2年重度慢性GVHD累积发生率分别为13.6%(95%CI 7.6%~21.3%)和12.9%(95%CI 5.1%~24.3%)(P=0.840)。

关键数值与推荐

  • haplo-cord-PBSCT组与UD-PBSCT组移植后2年累积复发率分别为12.8%(95%CI 7.0%~20.5%)和10.0%(95%CI 3.6%~20.2%)(P=0.341),非复发死亡率分别为14.7%(95%CI 8.4%~22.6%)和16.2%(95%CI 7.4%~28.0%)(P=0.681)。
  • haplo-cord-PBSCT组与UD-PBSCT组移植后2年总生存率分别为82.2%(95%CI 74.8%~90.3%)和75.5%(95%CI 64.2%~88.7%)(P=0.276),无病生存率分别为69.9%(95%CI 61.2%~79.8%)和73.8%(95%CI 62.4%~87.3%)(P=0.551),无GVHD无复发生存率分别为55.3%(95%CI 44.8%~64.8%)和64.7%(95%CI 52.8%~79.3%)(P=0.284)。

临床怎么用

  • 作者认为haplo-cord-PBSCT与UD-PBSCT治疗恶性血液病具有相似的疗效和安全性,可作为恶性血液病的替代治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives: To assess the efficacy of cord blood-assisted haploid peripheral blood stem cell transplantation (haplo-cord-PBSCT) versus unrelated donor peripheral blood stem cell transplantation (UD-PBSCT) in the treatment of malignant hematological diseases. Methods: A retrospective analysis was performed on one hundred and four patients with malignant hematological diseases who underwent haplo-cord-PBSCT and fifty-two patients who underwent UD-PBSCT at Xiangya Hospital of Central South University between January 2016 and December 2021. Results: ①The median implantation time for neutrophils in the haplo-cord-PBSCT and UD-PBSCT groups was 13 (9-22) days and 13 (10-24) days, respectively (P=0.834), whereas the median implantation time for platelets was 15 (7-103) days and 14 (8-38) days, respectively (P=0.816). The cumulative implantation rate of neutrophils at 30 days after transplantation in the haplo-cord-PBSCT group and the UD-PBSCT group was 100% (P=0.314), and the cumulative platelet implantation rate at 100 days after transplantation was 95.2% (95% CI 88.3% - 98.1% ) and 100% (P=0.927), respectively. 30 days after transplantation, both groups of patients achieved complete donor chimerism, and no umbilical cord blood stem cells were implanted. ②The cumulative incidence rates of grade Ⅱ-Ⅳ acute GVHD within 100 days after transplantation in the haplo-cord-PBSCT group and the UD-PBSCT group were 29.1% (95% CI 20.1% -38.1% ) and 28.8% (95% CI 17.2% -41.6% (P=0.965), respectively. The cumulative incidence rates of grade Ⅲ/Ⅳ acute GVHD were 7.8% (95% CI 3.6% -14.0% ) and 9.6% (95% CI 3.5% -19.5% ) (P=0.725). The cumulative incidence rates of 2-year chronic GVHD in the haplo-cord-PBSCT group and the UD-PBSCT group were 45.3% (95% CI 36.1% -56.1% ) and 35.1% (95% CI 21.6% -44.1% ), respectively (P=0.237). The cumulative incidence rates of severe chronic GVHD at 2 years after transplantation were 13.6% (95% CI 7.6% -21.3% ) and 12.9% (95% CI 5.1% -24.3% ), respectively (P=0.840). ③The 2-year CIR after transplantation in the haplo-cord-PBSCT group and UD-PBSCT group were 12.8% (95% CI 7.0% -20.5% ) and 10.0% (95% CI 3.6% -20.2% ), respectively (P=0.341), and the NRM were 14.7% (95% CI 8.4% -22.6% ) and 16.2% (95% CI 7.4% -28.0% ), respectively (P=0.681). ④The 2-year OS rates in the haplo-cord-PBSCT and UD-PBSCT groups after transplantation were 82.2% (95% CI 74.8% -90.3% ) and 75.5% (95% CI 64.2% -88.7% ), respectively (P=0.276). The 2-year DFS rates were 69.9% (95% CI 61.2% -79.8% ) and 73.8% (95% CI 62.4% -87.3% ), respectively (P=0.551). The 2-year rates of GVHD-free/recurrence-free survival (GRFS) were 55.3% (95% CI 44.8% -64.8% ) and 64.7% (95% CI 52.8% -79.3% ), respectively (P=0.284) . Conclusion: The findings of this study indicate that haplo-cord-PBSCT and UD-PBSCT have comparable efficacy and safety in the treatment of malignant hematological diseases and can be used as an alternative treatment options. 目的: 比较脐带血辅助单倍体外周血干细胞移植(haplo-cord-PBSCT)与无关供者外周血干细胞移植(UD-PBSCT)治疗恶性血液病的疗效。 方法: 对中南大学湘雅医院2016年1月至2021年12月的104例接受haplo-cord-PBSCT和52例接受UD-PBSCT)的恶性血液病患者进行回顾性分析。 结果: ①haplo-cord-PBSCT和UD-PBSCT组中性粒细胞中位植入时间分别为13(9~22)d、13(10~24)d(P=0.834),血小板植入中位时间分别为15(7~103)d、14(8~38)d(P=0.816)。haplo-cord-PBSCT组和UD-PBSCT组移植后30 d中性粒细胞累积植入率均为100.0%(P=0.314),移植后100 d血小板累积植入率分别为95.2%(95%CI 88.3%~98.1%)、100.0%(P=0.927)。移植后30 d两组患者均达到完全供者嵌合状态,未发生脐带血干细胞植入。②haplo-cord-PBSCT组与UD-PBSCT组移植后100 d内Ⅱ~Ⅳ度急性GVHD的累积发生率分别为29.1%(95%CI 20.1%~38.1%)、28.8%(95%CI 17.2%~41.6%(P=0.965),Ⅲ/Ⅳ度急性GVHD的累积发生率分别为7.8%(95%CI 3.6%~14.0%)、9.6%(95%CI 3.5%~19.5%)(P=0.725)。haplo-cord-PBSCT组与UD-PBSCT组2年慢性GVHD的累积发生率分别为45.3%(95%CI 36.1%~56.1%)、35.1%(95%CI 21.6%~44.1%)(P=0.237),移植后2年重度慢性GVHD的累积发生率分别为13.6%(95%CI 7.6%~21.3%)、12.9%(95%CI 5.1%~24.3%)(P=0.840)。③haplo-cord-PBSCT组、UD-PBSCT组移植后2年CIR分别为12.8%(95%CI 7.0%~20.5%)、10.0%(95%CI 3.6%~20.2%)(P=0.341),NRM分别为14.7%(95%CI 8.4%~22.6%)、16.2%(95%CI 7.4%~28.0%)(P=0.681)。④haplo-cord-PBSCT组、UD-PBSCT组移植后2年OS率分别为82.2%(95%CI 74.8%~90.3%)、75.5%(95%CI 64.2%~88.7%)(P=0.276),2年DFS率分别为69.9%(95%CI 61.2%~79.8%)、73.8%(95%CI 62.4%~87.3%)(P=0.551),2年无GVHD无复发生存(GRFS)率分别为55.3%(95%CI 44.8%~64.8%)、64.7%(95%CI 52.8%~79.3%)(P=0.284)。 结论: haplo-cord-PBSCT与UD-PBSCT治疗恶性血液病具有相似的疗效和安全性,可作为恶性血液病的替代治疗方案。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ma X, Chen Y, Liu Y, et al. [Haploidentical donor peripheral blood stem cell transplantation using third-party cord blood compared with matched unrelated donor transplantation for patients with hematologic malignancies]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 38604790. doi:10.3760/cma.j.cn121090-20230928-00149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。